[go: up one dir, main page]

ATE494373T2 - Verfahren und zusammensetzungen zur verringerung von hcv virusgenommengen in einer zielzelle - Google Patents

Verfahren und zusammensetzungen zur verringerung von hcv virusgenommengen in einer zielzelle Download PDF

Info

Publication number
ATE494373T2
ATE494373T2 AT05749437T AT05749437T ATE494373T2 AT E494373 T2 ATE494373 T2 AT E494373T2 AT 05749437 T AT05749437 T AT 05749437T AT 05749437 T AT05749437 T AT 05749437T AT E494373 T2 ATE494373 T2 AT E494373T2
Authority
AT
Austria
Prior art keywords
target cell
methods
compositions
hcv virus
reducing amounts
Prior art date
Application number
AT05749437T
Other languages
English (en)
Inventor
Peter Sarnow
Catherine Jopling
Alissa Lancaster
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35320743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE494373(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of ATE494373T2 publication Critical patent/ATE494373T2/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT05749437T 2004-05-04 2005-05-03 Verfahren und zusammensetzungen zur verringerung von hcv virusgenommengen in einer zielzelle ATE494373T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56835804P 2004-05-04 2004-05-04
PCT/US2005/015264 WO2005107816A2 (en) 2004-05-04 2005-05-03 Methods and compositions for reducing viral genome amounts in a target cell

Publications (1)

Publication Number Publication Date
ATE494373T2 true ATE494373T2 (de) 2011-01-15

Family

ID=35320743

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05749437T ATE494373T2 (de) 2004-05-04 2005-05-03 Verfahren und zusammensetzungen zur verringerung von hcv virusgenommengen in einer zielzelle

Country Status (15)

Country Link
US (6) US7307067B2 (de)
EP (3) EP2500431A3 (de)
JP (2) JP4943322B2 (de)
AT (1) ATE494373T2 (de)
AU (1) AU2005240118C1 (de)
CA (2) CA2564503C (de)
CY (1) CY1111755T1 (de)
DE (1) DE602005025751D1 (de)
DK (1) DK1747023T4 (de)
ES (1) ES2361458T5 (de)
IL (1) IL178679B (de)
PL (1) PL1747023T5 (de)
PT (1) PT1747023E (de)
SI (1) SI1747023T1 (de)
WO (1) WO2005107816A2 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1648914A4 (de) 2003-07-31 2009-12-16 Regulus Therapeutics Inc Oligomere verbindungen und zusammensetzungen zur verwendung bei der modulierung von kleinen nicht-kodienderen rnas
JP5654722B2 (ja) * 2003-11-26 2015-01-14 ユニバーシティ オブ マサチューセッツ 短鎖ｒｎａ機能の配列特異的阻害法
DE602005025751D1 (de) 2004-05-04 2011-02-17 Univ R Verfahren und zusammensetzungen zur verringerung von hcv virusgenommengen in einer zielzelle
AU2005250432B2 (en) 2004-05-28 2011-09-15 Asuragen, Inc. Methods and compositions involving microRNA
CA2857881A1 (en) 2004-11-12 2006-12-28 Asuragen, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
US20060293267A1 (en) * 2005-04-13 2006-12-28 University Of Massachusetts Dual functional oligonucleotides for use as anti-viral agents
WO2007021896A2 (en) 2005-08-10 2007-02-22 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides for use in modulating micro rna and uses thereof
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
DE602006019455D1 (de) 2005-08-29 2011-02-17 Regulus Therapeutics Inc Verfahren für mir-122a-modulation
US7516342B2 (en) 2005-12-30 2009-04-07 Intel Corporation Method, apparatus and system to dynamically choose an optimum power state
MX2008012219A (es) 2006-04-03 2008-10-02 Santaris Pharma As Composicion farmaceutica que comprende oligonucleotidos antisentido anti-miarn.
ES2569558T3 (es) * 2006-04-03 2016-05-11 Roche Innovation Center Copenhagen A/S Composición farmacéutica que comprende oligonucleótidos antisentido anti-ARNmi
CA2663878A1 (en) * 2006-09-19 2008-03-27 Asuragen, Inc. Mir-200 regulated genes and pathways as targets for therapeutic intervention
US8470791B2 (en) 2007-03-22 2013-06-25 Santaris Pharma A/S RNA antagonist compounds for the inhibition of Apo-B100 expression
WO2008113832A2 (en) 2007-03-22 2008-09-25 Santaris Pharma A/S SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF TARGET mRNA
JP5149528B2 (ja) * 2007-03-30 2013-02-20 学校法人東京医科大学 Ｃ型肝炎ウイルスの複製を制御するマイクロｒｎａ
US8415323B2 (en) * 2007-08-27 2013-04-09 The Regents Of The University Of California MicroRNAs for inhibiting viral replication
WO2009036332A1 (en) 2007-09-14 2009-03-19 Asuragen, Inc. Micrornas differentially expressed in cervical cancer and uses thereof
AU2008306327B2 (en) * 2007-10-04 2014-05-15 Roche Innovation Center Copenhagen A/S Micromirs
WO2009070805A2 (en) 2007-12-01 2009-06-04 Asuragen, Inc. Mir-124 regulated genes and pathways as targets for therapeutic intervention
US8404659B2 (en) * 2008-03-07 2013-03-26 Santaris Pharma A/S Pharmaceutical compositions for treatment of MicroRNA related diseases
EP2990487A1 (de) 2008-05-08 2016-03-02 Asuragen, INC. Zusammensetzungen und verfahren in zusammenhang mit der mirna-modulation von neovaskularisation oder angiogenese
ES2541442T3 (es) 2008-08-01 2015-07-20 Roche Innovation Center Copenhagen A/S Modulación mediada por microARN de factores estimulantes de colonias
US8691971B2 (en) 2008-09-23 2014-04-08 Scott G. Petersen Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating RNA interference
EP2191834A1 (de) * 2008-11-26 2010-06-02 Centre National De La Recherche Scientifique (Cnrs) Zusammensetzungen und Verfahren zur Behandlung von Retrovireninfektionen
WO2010122538A1 (en) * 2009-04-24 2010-10-28 Santaris Pharma A/S Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon
EP2456870A1 (de) 2009-07-21 2012-05-30 Santaris Pharma A/S Auf pcsk9 gerichtete antisense-oligomere
DK2558578T3 (en) 2010-04-13 2016-01-25 Life Technologies Corp CONFIGURATIONS AND METHODS FOR INHIBITION OF nucleic acid function
ES2699630T3 (es) 2010-04-23 2019-02-12 Cold Spring Harbor Laboratory Novedosos ARNhc diseñados estructuralmente
WO2012097261A2 (en) 2011-01-14 2012-07-19 The General Hospital Corporation Methods targeting mir-128 for regulating cholesterol/lipid metabolism
WO2013040251A2 (en) 2011-09-13 2013-03-21 Asurgen, Inc. Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
AU2013201406B2 (en) 2011-10-21 2014-10-02 Abbvie Ireland Unlimited Company Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
EP2583680A3 (de) 2011-10-21 2013-06-12 Abbvie Inc. Einzel- (PSI-7977) oder Kombinationsbehandlung in der Verwendung zur Behandlung von HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
SG10201803157XA (en) 2013-05-01 2018-05-30 Regulus Therapeutics Inc Microrna compounds and methods for modulating mir-122
MX391977B (es) 2013-06-27 2025-03-21 Roche Innovation Ct Copenhagen As Oligómeros antisentido y conjugados con diana en la proteína-convertasa subtilisina/kexina tipo 9(pcsk9).
US10556020B2 (en) 2014-09-26 2020-02-11 University Of Massachusetts RNA-modulating agents
BR112017009504A2 (pt) 2014-11-10 2018-02-06 Glaxosmithkline Ip No 2 Ltd métodos para tratar e para curar uma infecção por hcv, e, composição farmacêutica.
EA201790778A1 (ru) 2014-11-10 2017-11-30 Глаксосмитклайн Интеллекчуал Проперти (№2) Лимитед Фармацевтические композиции длительного действия от гепатита с
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
JP7279081B2 (ja) 2018-05-08 2023-05-22 レグルス セラピューティクス インコーポレイテッド Ｍｉｒ－１２２を調節するためのマイクロｒｎａ化合物及び方法
CN111904973B (zh) * 2020-07-27 2021-12-03 中国农业科学院兰州兽医研究所 ssc-miR-122在制备调节猪繁殖与呼吸综合征病毒复制的药物中的应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
DE69034078T2 (de) 1989-03-21 2004-04-01 Vical, Inc., San Diego Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
US5610050A (en) * 1990-04-20 1997-03-11 The General Hospital Corporation Methods of preventing viral replication
JPH06311885A (ja) 1992-08-25 1994-11-08 Mitsubishi Kasei Corp Ｃ型肝炎ウイルス遺伝子に相補的なアンチセンス化合物
US6423489B1 (en) 1992-09-10 2002-07-23 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of Hepatitis C virus-associated diseases
US5985847A (en) 1993-08-26 1999-11-16 The Regents Of The University Of California Devices for administration of naked polynucleotides which encode biologically active peptides
WO1995030746A1 (en) 1994-05-10 1995-11-16 The General Hospital Corporation Antisense inhibition of hepatitis c virus
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
US5985310A (en) 1996-08-09 1999-11-16 Alcon Laboratories, Inc. Preservative systems for pharmaceutical compositions containing cyclodextrins
US6824768B2 (en) * 1998-12-18 2004-11-30 Schering Corporation Ribavirin-pegylated interferon alfa induction HCV combination therapy
CA2442092A1 (en) * 2001-03-26 2002-10-17 Ribozyme Pharmaceuticals, Inc. Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
IL161100A0 (en) * 2001-09-28 2004-08-31 Max Planck Gesellschaft Identification of novel genes coding for small temporal rnas
FR2830254B1 (fr) * 2001-09-28 2004-09-17 Synkem Nouvelles diphosphines, leurs complexes avec des metaux de transition et leur utilisation en synthese asymetrique
JP2005517427A (ja) 2002-02-20 2005-06-16 サーナ・セラピューティクス・インコーポレイテッド 短干渉核酸（ｓｉＮＡ）を用いるＣ型肝炎ウイルス（ＨＣＶ）遺伝子発現のＲＮＡ干渉媒介性阻害
US20040175732A1 (en) 2002-11-15 2004-09-09 Rana Tariq M. Identification of micrornas and their targets
EP1592791A2 (de) * 2003-02-10 2005-11-09 National Institute of Advanced Industrial Science and Technology Regulation der genexpression durch dna-interferenz
JP2006517960A (ja) * 2003-02-18 2006-08-03 ファイザー インコーポレイテッド Ｃ型肝炎ウイルスの阻害剤、それを使用する組成物および治療法
EP1648914A4 (de) * 2003-07-31 2009-12-16 Regulus Therapeutics Inc Oligomere verbindungen und zusammensetzungen zur verwendung bei der modulierung von kleinen nicht-kodienderen rnas
US20070270361A1 (en) 2003-08-04 2007-11-22 Shan Lu Sars Nucleic Acids, Proteins, Vaccines, and Uses Thereof
CA2532795A1 (en) 2003-08-07 2005-02-17 Avi Biopharma, Inc. Sense antiviral compound and method for treating ssrna viral infection
JP5654722B2 (ja) * 2003-11-26 2015-01-14 ユニバーシティ オブ マサチューセッツ 短鎖ｒｎａ機能の配列特異的阻害法
DE602005025751D1 (de) 2004-05-04 2011-02-17 Univ R Verfahren und zusammensetzungen zur verringerung von hcv virusgenommengen in einer zielzelle
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
DK1931780T3 (en) 2005-08-29 2016-01-25 Regulus Therapeutics Inc Antisense-forbindelser med forøget anti-microrna-aktivitet
MX2008012219A (es) 2006-04-03 2008-10-02 Santaris Pharma As Composicion farmaceutica que comprende oligonucleotidos antisentido anti-miarn.
AU2008306327B2 (en) 2007-10-04 2014-05-15 Roche Innovation Center Copenhagen A/S Micromirs
WO2011000092A1 (en) 2009-06-29 2011-01-06 Matthew Hunsberger A disc brake for a tape measure

Also Published As

Publication number Publication date
US8217020B2 (en) 2012-07-10
AU2005240118C1 (en) 2014-02-13
DK1747023T4 (en) 2016-05-02
US9416362B2 (en) 2016-08-16
EP1747023A2 (de) 2007-01-31
SI1747023T1 (sl) 2011-06-30
ES2361458T5 (es) 2016-04-20
CA2564503C (en) 2015-12-29
EP1747023B1 (de) 2011-01-05
AU2005240118B2 (en) 2011-09-08
US20050288245A1 (en) 2005-12-29
PL1747023T3 (pl) 2011-08-31
US8759312B2 (en) 2014-06-24
US7307067B2 (en) 2007-12-11
US7838504B2 (en) 2010-11-23
JP2007536242A (ja) 2007-12-13
PL1747023T5 (pl) 2017-05-31
CA2912903A1 (en) 2005-11-17
EP1747023A4 (de) 2010-03-03
EP2500431A2 (de) 2012-09-19
PT1747023E (pt) 2011-04-11
US20110124707A1 (en) 2011-05-26
AU2005240118A1 (en) 2005-11-17
EP2338996A3 (de) 2013-12-18
JP2012102116A (ja) 2012-05-31
EP2500431A3 (de) 2013-12-18
CY1111755T1 (el) 2015-10-07
JP4943322B2 (ja) 2012-05-30
DK1747023T3 (da) 2011-04-18
IL178679A0 (en) 2007-02-11
US20150005362A1 (en) 2015-01-01
ES2361458T3 (es) 2011-06-17
EP2338996A2 (de) 2011-06-29
EP1747023B2 (de) 2016-03-09
CA2564503A1 (en) 2005-11-17
WO2005107816A2 (en) 2005-11-17
US20120329856A1 (en) 2012-12-27
US20160348116A1 (en) 2016-12-01
JP5602123B2 (ja) 2014-10-08
IL178679B (en) 2019-01-31
DE602005025751D1 (de) 2011-02-17
WO2005107816A3 (en) 2006-02-23
US20080234220A1 (en) 2008-09-25

Similar Documents

Publication Publication Date Title
ATE494373T2 (de) Verfahren und zusammensetzungen zur verringerung von hcv virusgenommengen in einer zielzelle
WO2008033466A3 (en) Compositions and methods for treatment of viral diseases
EA200700243A1 (ru) Способы лечения гепатита с
WO2011123645A3 (en) Nucleoside phosphoramidates
WO2006012078A3 (en) Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
WO2007084413A3 (en) Methods for treating hepatitis c
WO2005123087A3 (en) C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
WO2008085508A3 (en) Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
ATE475660T1 (de) Antivirale verbindungen
WO2008133753A3 (en) Anti-viral compounds
WO2010047830A3 (en) Agents for hcv treatment
WO2007081517A3 (en) Anti-viral compounds
WO2004009020A3 (en) Pyrrolopyrimidine thionucleoside analogs as antivirals
EP2609923A3 (de) Nukleosid-Phosphoramidate
BRPI0811633A2 (pt) compostos de fórmulas (i) e (ii), método de tratamento de hospedeiro infectado por hiv-1, hiv-2, hbv ou hcv, método de prevenção de infecção por hiv-1, hiv-2, hbv ou hcv, método para reduzir atividade biológica de infecção por hiv-1, hiv-2, hbv ou hcv e composição farmacêutica
ZA200805304B (en) Anti-viral compounds
EP2853531A3 (de) Antivirale Verbindungen
BRPI0515596A (pt) composição farmacêutica usada para o tratamento e/ou prevenção de hcv, e, métodos de inibir rna polimerase ns5b de hepatite c de tratar ou prevenir infecção por hepatite c em um mamìfero
WO2007084435A3 (en) Methods for treating hepatitis c
ATE551343T1 (de) Tetracyclische verbindungen zur behandlung von hepatitis c
WO2010055164A3 (en) Isoquinolone derivatives as inhibitors of plavivirus replication
WO2009029384A3 (en) Compounds for the treatment of hepatitis c
ATE505473T1 (de) Cyclopropylkondensierte indolobenzazepinderivate zur behandlung von hepatitis c
ATE498398T1 (de) Cycloalkyl-heterozyklen zur behandlung des hepatitis-c-virus
WO2005051318A3 (en) Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1747023

Country of ref document: EP